bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S2 from A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer
Authors: Zanoni Daniella K. , Demétrio De Souza França Paula , Valero Cristina , Peterson Gary , Ardigo Marco , Ghossein Ronald , Dusza Stephen W. , Matsuura Danielli , Scholfield Daniel W. , Adilbay Dauren , Montero Pablo H. , Migliacci Jocelyn , Pillarsetty Naga Vara Kishore , Kose Kivanc , Ganly Ian , Rajadhyaksha Milind , Patel Snehal G.
Published: June 2024

Supplementary Figure S2 displays in vivo Reflectance Confocal Microscopy (RCM) images of a tumor area in a 58-year-old male. This patient was a never smoker but had a history of 35 years of daily alcohol exposure. The tumor was identified as a 3.7 cm ulcerated moderately differentiated oral squamous cell carcinoma located on the left lateral tongue.
Supplementary Figure S1 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer
Authors: Han Yoo Jane , Liu Siyao , Hardeman Ashley , Rajagopal Padma Sheila , Mueller Jeffrey , Khramtsova Galina , Sanni Ayodele , Ajani Mustapha , Clayton Wendy , Hurley Ian W. , Yoshimatsu Toshio F. , Zheng Yonglan , Parker Joel , Perou Charles M. , Olopade Olufunmilayo I.
Published: June 2024

Supplementary Fig. S1. Correlation with T-Cell Immune Module Scores.
Supplementary Figure S10 from A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer
Authors: Zanoni Daniella K. , Demétrio De Souza França Paula , Valero Cristina , Peterson Gary , Ardigo Marco , Ghossein Ronald , Dusza Stephen W. , Matsuura Danielli , Scholfield Daniel W. , Adilbay Dauren , Montero Pablo H. , Migliacci Jocelyn , Pillarsetty Naga Vara Kishore , Kose Kivanc , Ganly Ian , Rajadhyaksha Milind , Patel Snehal G.
Published: June 2024

Supplementary Figure S10 shows in vivo RCM images of a tumor area in a 73-year-old male, with a 12-year/packs exposure to tobacco and daily alcohol exposure, harboring a 2.5 cm moderately differentiated oral squamous cell carcinoma of the left lateral tongue.
Supplementary Figure S1 from A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer
Authors: Zanoni Daniella K. , Demétrio De Souza França Paula , Valero Cristina , Peterson Gary , Ardigo Marco , Ghossein Ronald , Dusza Stephen W. , Matsuura Danielli , Scholfield Daniel W. , Adilbay Dauren , Montero Pablo H. , Migliacci Jocelyn , Pillarsetty Naga Vara Kishore , Kose Kivanc , Ganly Ian , Rajadhyaksha Milind , Patel Snehal G.
Published: June 2024

Supplementary Figure S1 illustrates that hyperkeratosis is a frequently seen feature in oral squamous cell carcinoma, as cells produce keratin.
Supplementary Table S1 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Authors: Moyer Cassandra L. , Lanier Amanda , Qian Jing , Coleman Darian , Hill Jamal , Vuligonda Vidyasagar , Sanders Martin E. , Mazumdar Abhijit , Brown Powel H.
Published: June 2024

Supplementary table listing qPCR primers and probes used in methods
Supplementary Figure S5 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Authors: Moyer Cassandra L. , Lanier Amanda , Qian Jing , Coleman Darian , Hill Jamal , Vuligonda Vidyasagar , Sanders Martin E. , Mazumdar Abhijit , Brown Powel H.
Published: June 2024

Supplementary figure with cell line protein expression
Supplementary Figure S4 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Authors: Moyer Cassandra L. , Lanier Amanda , Qian Jing , Coleman Darian , Hill Jamal , Vuligonda Vidyasagar , Sanders Martin E. , Mazumdar Abhijit , Brown Powel H.
Published: June 2024

Supplementary figure with cell line apoptosis rescue
Supplementary Table 8 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

Clinical Table of University of Michigan patients that were utilized for survival analysis with corresponding CXCL8 and CA19-9 plasma values
Supplementary Table 5 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

Organoid Luminex Assay
Supplementary Figure S5 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Desai Kunal B. , Serritella Anthony V. , Stadler Walter M. , O'Donnell Peter H. , Sweis Randy F. , Szmulewitz Russell Z.
Published: June 2024

Figure S5: Maximal change in PSA from Baseline to lowest PSA value while on trial
Supplementary Figure S4 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Desai Kunal B. , Serritella Anthony V. , Stadler Walter M. , O'Donnell Peter H. , Sweis Randy F. , Szmulewitz Russell Z.
Published: June 2024

Figure S4: Comparison of Day 28 Cortisol Levels Between Dosing Cohorts
Supplementary Table 4 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

TCGA Timer 2.0 Analysis
Supplementary Table 2 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

Univariate Survival Analysis
Supplementary Figure S1 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Desai Kunal B. , Serritella Anthony V. , Stadler Walter M. , O'Donnell Peter H. , Sweis Randy F. , Szmulewitz Russell Z.
Published: June 2024

Figure S1: Dose level determination schema
Supplementary Fig 6 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

CXCL8 is expressed in a unique subpopulation of tumor epithelial cells and in tumor infiltrating granulocytes.
Supplementary Fig 5 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

CXCL8 and KRT17 tumor epithelial expression trends with worse survival.
Supplementary Fig 4 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

CXCL8 is co-expressed with KRT17 and CLDN18 in a unique subpopulation of tumor epithelial cells.
Supplementary Table S5 from Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Authors: Jamieson Amy , Sobral de Barros Juliana , Cochrane Dawn R. , Douglas J. Maxwell , Shankar Sameer , Lynch Branden J. , Leung Samuel , Martin Spencer , Senz Janine , Lum Amy , Drew Yvette , Gilks C. Blake , Huntsman David G. , McAlpine Jessica N.
Published: June 2024

Supplemental Table 5: Association of Signatures and CCNE1 amplification, p-values using Fisher’s Exact test
Supplementary Table S3 from Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Authors: Jamieson Amy , Sobral de Barros Juliana , Cochrane Dawn R. , Douglas J. Maxwell , Shankar Sameer , Lynch Branden J. , Leung Samuel , Martin Spencer , Senz Janine , Lum Amy , Drew Yvette , Gilks C. Blake , Huntsman David G. , McAlpine Jessica N.
Published: June 2024

Supplemental table 3. Regions of copy-number gain and loss
Supplementary Table S2 from Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Authors: Jamieson Amy , Sobral de Barros Juliana , Cochrane Dawn R. , Douglas J. Maxwell , Shankar Sameer , Lynch Branden J. , Leung Samuel , Martin Spencer , Senz Janine , Lum Amy , Drew Yvette , Gilks C. Blake , Huntsman David G. , McAlpine Jessica N.
Published: June 2024

Supplemental Table 2 – Immunohistochemistry and copy number scores for HER2 (ERBB2)
Supplementary Fig 1 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

Supplementary epithelial analysis of human PDAC single cell RNA sequencing.
Supplementary Table S1 from Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Authors: Jamieson Amy , Sobral de Barros Juliana , Cochrane Dawn R. , Douglas J. Maxwell , Shankar Sameer , Lynch Branden J. , Leung Samuel , Martin Spencer , Senz Janine , Lum Amy , Drew Yvette , Gilks C. Blake , Huntsman David G. , McAlpine Jessica N.
Published: June 2024

Supplemental Table 1: Clinicopathologic characteristics of the total cohort
Supplementary Table S4 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Authors: Agarwal Neeraj , Castellano Daniel , Alonso-Gordoa Teresa , Arranz Arija Jose Angel , Colomba Emeline , Gravis Gwenaelle , Mourey Loic , Oudard Stephane , Fléchon Aude , González Macarena , Rey Pablo M. , Schweizer Michael T. , Gallardo Enrique , Johnston Erica , Balar Arjun , Haddad Nadine , Appiah Adams K. , Nacerddine Karim , Piulats José M.
Published: June 2024

List of secondary endpoints and corresponding outcomes.
Supplementary Table S3 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Authors: Agarwal Neeraj , Castellano Daniel , Alonso-Gordoa Teresa , Arranz Arija Jose Angel , Colomba Emeline , Gravis Gwenaelle , Mourey Loic , Oudard Stephane , Fléchon Aude , González Macarena , Rey Pablo M. , Schweizer Michael T. , Gallardo Enrique , Johnston Erica , Balar Arjun , Haddad Nadine , Appiah Adams K. , Nacerddine Karim , Piulats José M.
Published: June 2024

Best overall response by RECIST v1.1 criteria without concurrent bone progression.
Supplementary Figure S5 from Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Authors: Jamieson Amy , Sobral de Barros Juliana , Cochrane Dawn R. , Douglas J. Maxwell , Shankar Sameer , Lynch Branden J. , Leung Samuel , Martin Spencer , Senz Janine , Lum Amy , Drew Yvette , Gilks C. Blake , Huntsman David G. , McAlpine Jessica N.
Published: June 2024

Supplemental figure 5. Plot summarizing the relationship between BriTROC signature exposures per sample, targeted panel mutations, copy number status, and various clinical correlates
Supplementary Table S2 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Authors: Agarwal Neeraj , Castellano Daniel , Alonso-Gordoa Teresa , Arranz Arija Jose Angel , Colomba Emeline , Gravis Gwenaelle , Mourey Loic , Oudard Stephane , Fléchon Aude , González Macarena , Rey Pablo M. , Schweizer Michael T. , Gallardo Enrique , Johnston Erica , Balar Arjun , Haddad Nadine , Appiah Adams K. , Nacerddine Karim , Piulats José M.
Published: June 2024

List for representativeness of study participants.
Supplementary Table S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Authors: Agarwal Neeraj , Castellano Daniel , Alonso-Gordoa Teresa , Arranz Arija Jose Angel , Colomba Emeline , Gravis Gwenaelle , Mourey Loic , Oudard Stephane , Fléchon Aude , González Macarena , Rey Pablo M. , Schweizer Michael T. , Gallardo Enrique , Johnston Erica , Balar Arjun , Haddad Nadine , Appiah Adams K. , Nacerddine Karim , Piulats José M.
Published: June 2024

List of study key endpoints and definitions.
Supplementary Figure S2 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Authors: Agarwal Neeraj , Castellano Daniel , Alonso-Gordoa Teresa , Arranz Arija Jose Angel , Colomba Emeline , Gravis Gwenaelle , Mourey Loic , Oudard Stephane , Fléchon Aude , González Macarena , Rey Pablo M. , Schweizer Michael T. , Gallardo Enrique , Johnston Erica , Balar Arjun , Haddad Nadine , Appiah Adams K. , Nacerddine Karim , Piulats José M.
Published: June 2024

Kaplan-Meier curve of time to symptomatic progression.
Supplementary Figure S11 from Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Authors: Jamieson Amy , Sobral de Barros Juliana , Cochrane Dawn R. , Douglas J. Maxwell , Shankar Sameer , Lynch Branden J. , Leung Samuel , Martin Spencer , Senz Janine , Lum Amy , Drew Yvette , Gilks C. Blake , Huntsman David G. , McAlpine Jessica N.
Published: June 2024

Supplemental figure 11. Kaplan-Meier survival analyses demonstrating no difference in PFS in p53abn EC patients with endometrioid tumors compared to non-endometrioid tumors (carcinosarcoma, clear cell, serous and other) once adjusting for FIGO stage.
Supplementary Table 5 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

Supplementary Table 5. Multivariate analysis of progression-free survival in patients treated with first-line ICI+TKI.
Supplementary Figure S7 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
Authors: Schatz Christoph A. , Zitzmann-Kolbe Sabine , Moen Ingrid , Klotz Monika , Nair Shankari , Stargard Stefan , Bjerke Roger M. , Wickstrøm Biseth Katrine , Feng Yuan Zeng , Indrevoll Bård , Cruciani Veronique , Karlsson Jenny , Haendler Bernard , Nielsen Carsten H. , Alfsen Maria Z. , Hammer Stefanie , Hennekes Hartwig , Cuthbertson Alan , Hagemann Urs B. , Larsen Åsmund
Published: June 2024

Figure S7. Distribution of 225Ac-pelgi and 225Ac-DOTA-pelgi in the MDA-PCa-2b prostate cancer CDX model.
Supplementary Figure S6 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
Authors: Schatz Christoph A. , Zitzmann-Kolbe Sabine , Moen Ingrid , Klotz Monika , Nair Shankari , Stargard Stefan , Bjerke Roger M. , Wickstrøm Biseth Katrine , Feng Yuan Zeng , Indrevoll Bård , Cruciani Veronique , Karlsson Jenny , Haendler Bernard , Nielsen Carsten H. , Alfsen Maria Z. , Hammer Stefanie , Hennekes Hartwig , Cuthbertson Alan , Hagemann Urs B. , Larsen Åsmund
Published: June 2024

Figure S6. Growth curves of individual tumors in KUCaP-1 tumor-bearing male scid/scid mice treated with (A) vehicle, (B) 225Ac-isotype control, (C) 75 kBq/kg 225Ac-pelgi, (D) 150 kBq/kg 225Ac-pelgi, (E) 300 kBq/kg 225Ac-pelgi, or (F) large tumors (mean volume at treatment start 470 mm3) treated with 300 kBq/kg 227Th-pelgi. T
Supplementary Table 1 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

Supplementary Table 1. Baseline characteristics of patients with localized FH-deficient RCC.
Supplementary Figure S3 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
Authors: Schatz Christoph A. , Zitzmann-Kolbe Sabine , Moen Ingrid , Klotz Monika , Nair Shankari , Stargard Stefan , Bjerke Roger M. , Wickstrøm Biseth Katrine , Feng Yuan Zeng , Indrevoll Bård , Cruciani Veronique , Karlsson Jenny , Haendler Bernard , Nielsen Carsten H. , Alfsen Maria Z. , Hammer Stefanie , Hennekes Hartwig , Cuthbertson Alan , Hagemann Urs B. , Larsen Åsmund
Published: June 2024

Figure S3. Growth curves of individual tumors in C4-2 tumor-bearing male BALB/c nude mice treated with (A) vehicle, (B) 225Ac-isotype control, (C) 300 kBq/kg 225Ac-DOTA-J591, (D) 300 kBq/kg 225AcDOTA-pelgi, (E) 300 kBq/kg 225Ac-pelgi, or (F) 300 kBq/kg 227Th-pelgi.
Supplementary Figure 6 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

Supplementary Figure 6. Validation of the FH-deficient RCC immune signature. (A) UMAP plot showing expression of selected genes; (B) Correlations between the expression of six genes in the FH-deficient RCC immune signature and treatment response, significance of differential signature expression (q value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction; (C) Correlations between the expression of FH-deficient RCC signature and several immune related hallmark pathways, significance of differential signature expression (q value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction. *, q<0.05; **, q<0.01; ***, q<0.001; ****, q<0.0001.
Supplementary Figure 5 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

Supplementary Figure 5. Cell clusters and their distribution in a validation cohort by Dong et al.. (A) UMAP plot showing the sample distribution of T cells; (B) UMAP plot of all T cells collected from four samples; (C) Dot plot of marker gene expression for T clusters; (D) Bar plots showing tissue distribution of the T cells; (E) Tissue prevalence of T cell clusters estimated by Ro/e score.
Supplementary Figure 3 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

Supplementary Figure 3. Forest plot showing the prognostic value of clinicopathologic and molecular features in patients treated with first-line ICI+TKI combination therapy. HR<1 indicates better survival in the comparator group, while HR>1 indicates better survival in the control group. TMB, tumor mutation burden; MUT, mutation; WT, wild type; TPS, tumor proportion score; CCP, cell cycle progression; Sig., signature.
Supplementary Figure 2 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

Supplementary Figure 2. Treatment details and survival outcomes of patients with metastatic FH-deficient RCC. (A) Swimmer plot showing the treatment response and duration of each patient receiving first-line systemic treatments; (B) Progression-free survival for patients receiving first-line systemic treatments; (C) Overall survival (OS) for patients receiving first-line systemic treatments.
Supplementary Table S1 from Stabilizing Tumor-Resident Mast Cells Restores T-Cell Infiltration and Sensitizes Sarcomas to PD-L1 Inhibition
Authors: Panagi Myrofora , Mpekris Fotios , Voutouri Chrysovalantis , Hadjigeorgiou Andreas G. , Symeonidou Chloe , Porfyriou Eleni , Michael Christina , Stylianou Andreas , Martin John D. , Cabral Horacio , Constantinidou Anastasia , Stylianopoulos Triantafyllos
Published: June 2024

The parameters of the model that predict the tumor growth rate after treatment (V_r=a E+b V_0+c E V_0+d). The predicted values are presented in Fig. 6C.
Supplementary Methods S1 from Stabilizing Tumor-Resident Mast Cells Restores T-Cell Infiltration and Sensitizes Sarcomas to PD-L1 Inhibition
Authors: Panagi Myrofora , Mpekris Fotios , Voutouri Chrysovalantis , Hadjigeorgiou Andreas G. , Symeonidou Chloe , Porfyriou Eleni , Michael Christina , Stylianou Andreas , Martin John D. , Cabral Horacio , Constantinidou Anastasia , Stylianopoulos Triantafyllos
Published: June 2024

Materials and methods
Supplementary Tables 1 from Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk
Authors: Silver Alexander J. , Vlasschaert Caitlyn , Mack Taralynn , Sharber Brian , Xu Yaomin , Bick Alexander G. , Pinson C. Wright , Savona Michael R.
Published: June 2024

Supplementary Tables S1-S29
Supplementary Methods 1 from Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk
Authors: Silver Alexander J. , Vlasschaert Caitlyn , Mack Taralynn , Sharber Brian , Xu Yaomin , Bick Alexander G. , Pinson C. Wright , Savona Michael R.
Published: June 2024

Supplementary Methods
Supplementary Figure S5 from Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk
Authors: Silver Alexander J. , Vlasschaert Caitlyn , Mack Taralynn , Sharber Brian , Xu Yaomin , Bick Alexander G. , Pinson C. Wright , Savona Michael R.
Published: June 2024

Supplementary Figure S5. Significant associations between transplant medication exposures and CHIP mutations in All of Us.
Supplementary Figure S3 from Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk
Authors: Silver Alexander J. , Vlasschaert Caitlyn , Mack Taralynn , Sharber Brian , Xu Yaomin , Bick Alexander G. , Pinson C. Wright , Savona Michael R.
Published: June 2024

Supplementary Figure S3. Characterization of clonal hematopoiesis of indeterminate potential in the UK Biobank cohort.
Supplementary Table S9 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Table 9.
Baseline characteristics of patients included in the gut microbiota analysis.
Supplementary Table S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Table 8.
Baseline characteristics of patients included in the circulating tumour DNA analysis.
Supplementary Table S7 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Table 7.
Mean scores of EORTC QLQ-C30 and QLQ-HCC18 questionnaires at baseline and at the end of treatment
Supplementary Table S7 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Authors: Liu Jiangang , Moura David S. , Jones Robin L. , Aggarwal Amit , Ebert Philip J. , Wagner Andrew J. , Wright Jennifer , Martin-Broto Javier , Tap William D.
Published: June 2024

List of significant genes of REDSARC-refined gene signature
Supplementary Table S3 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Table 3. Mass cytometry panels.
Supplementary Table S5 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Authors: Liu Jiangang , Moura David S. , Jones Robin L. , Aggarwal Amit , Ebert Philip J. , Wagner Andrew J. , Wright Jennifer , Martin-Broto Javier , Tap William D.
Published: June 2024

Associations between the BOR signature and clinical variables
Supplementary Table S4 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Authors: Liu Jiangang , Moura David S. , Jones Robin L. , Aggarwal Amit , Ebert Philip J. , Wagner Andrew J. , Wright Jennifer , Martin-Broto Javier , Tap William D.
Published: June 2024

Pathway over-representation analysis for REDSARC genes
Supplementary Table S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Authors: Liu Jiangang , Moura David S. , Jones Robin L. , Aggarwal Amit , Ebert Philip J. , Wagner Andrew J. , Wright Jennifer , Martin-Broto Javier , Tap William D.
Published: June 2024

Baseline demographic characteristics in ANNOUNCE
Supplementary Methods S5 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Methods 5. Complete list of the targeted genes profiled using the NanoString PanCancer Immune panel.
Supplementary Methods S3 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Methods 3: Circulating Free DNA
Supplementary Methods S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Methods 2: Overview of Biomarker analysis.
Supplementary Methods S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Methods 1: Analysis of health-related quality of life.
Supplementary Figure S7 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Figure S7.
Radar chart of symptom scales according to EORTC QLQ-C30 (Top Panel) and EORTC QLQ-HCC18 (Bottom Panel) symptom scales. Values are reported as means and scale score range is 0-100. Higher scores indicate more symptoms.
Supplementary Figure S8 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Authors: Iwase Toshiaki , Cohen Evan N. , Gao Hui , Alexander Angela , Kai Megumi , Chiv Vivian , Wang Xiaoping , Krishnamurthy Savitri , Liu Diane , Shen Yu , Kida Kumiko , Reuben Alexandre , Layman Rachel M. , Ramirez David L. , Tripathy Debasish , Moulder Stacy L. , Yam Clinton , Valero Vicente , Lim Bora , Reuben James M. , Ueno Naoto T.
Published: June 2024

Supplementary Figure 8. De novo cytokine synthesis by TLR-activated dendritic cells
Supplementary Figure S5 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Figure S5.
Mean scores of global health status (GHS)/quality of life (QoL) and functioning domains on EORTC QLQ-C30 questionnaire at baseline and at the end of treatment.
Supplementary Figure S6 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Authors: Iwase Toshiaki , Cohen Evan N. , Gao Hui , Alexander Angela , Kai Megumi , Chiv Vivian , Wang Xiaoping , Krishnamurthy Savitri , Liu Diane , Shen Yu , Kida Kumiko , Reuben Alexandre , Layman Rachel M. , Ramirez David L. , Tripathy Debasish , Moulder Stacy L. , Yam Clinton , Valero Vicente , Lim Bora , Reuben James M. , Ueno Naoto T.
Published: June 2024

Supplementary Figure 6. Progression-free survival and overall survival stratified by clonality in patients with PD-L1–negative tumors per IHC analysis (N = 32).
Supplementary Figure S4 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Authors: Iwase Toshiaki , Cohen Evan N. , Gao Hui , Alexander Angela , Kai Megumi , Chiv Vivian , Wang Xiaoping , Krishnamurthy Savitri , Liu Diane , Shen Yu , Kida Kumiko , Reuben Alexandre , Layman Rachel M. , Ramirez David L. , Tripathy Debasish , Moulder Stacy L. , Yam Clinton , Valero Vicente , Lim Bora , Reuben James M. , Ueno Naoto T.
Published: June 2024

Supplementary Figure 4. Progression-free survival and overall survival stratified by PD-L1 IHC status (n = 32).
Supplementary Figure S3 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Figure S3.
Manual gating scheme used for analysis of peripheral immune landscape. Live singlet CD45+ were gated on CD3+CD19- and CD3-CD19+ cells. T cells were further gated on CD4 T cells, CD8 T cells, MAIT cells, gd T cells and NKT cells.
Supplementary Figure S3 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Authors: Iwase Toshiaki , Cohen Evan N. , Gao Hui , Alexander Angela , Kai Megumi , Chiv Vivian , Wang Xiaoping , Krishnamurthy Savitri , Liu Diane , Shen Yu , Kida Kumiko , Reuben Alexandre , Layman Rachel M. , Ramirez David L. , Tripathy Debasish , Moulder Stacy L. , Yam Clinton , Valero Vicente , Lim Bora , Reuben James M. , Ueno Naoto T.
Published: June 2024

Supplementary Figure 3. Overall survival duration stratified by the response to prior chemotherapy.
Supplementary Figure S13 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Figure S13.
Relative abundance of gut bacteria at genus level in the microbiota-evaluable population at screening and at the end of treatment (EOT), represented with bar charts.
Supplementary Figure S12 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Figure S12.
A. Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hochberg P-values are correlated to fold-changes in transcripts identified in samples from responders (n = 4) versus non-responders (n = 6). Transcripts achieving the highest statistical significance (p value <0.05) are highlighted by the presence of the corresponding gene name and are highlighted in the Heat Map shown in Panel B.
Supplementary Figure 7 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Authors: Rolfo Christian D. , Madison Russell W. , Pasquina Lincoln W. , Brown Derek W. , Huang Yanmei , Hughes Jason D. , Graf Ryon P. , Oxnard Geoffrey R. , Husain Hatim
Published: June 2024

Supplementary Figure 7: KRAS mutations detected in tissue biopsy from patients which were excluded from figure 5B and not considered eligible for targeted therapy.
Supplementary Figure S11 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Figure S11.
Heatmap of the 770 transcripts analysed with the Nanostring Pancancer Immune Panel on the baseline biopsies of patients achieving a response at 12 weeks (responders) and non-responders (A). Panel B represents the Gene-set enrichment analysis (GSEA) showing the differential regulation of 22 gene expression signatures on the basis of radiological response at 12 weeks. Methodologic information for the GSEA and its interpretation is provided as Supplementary Methods.